Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Bicycle Therapeutics (BCYC) Net Margin (2018 - 2025)

Bicycle Therapeutics (BCYC) has disclosed Net Margin for 8 consecutive years, with 503.66% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Net Margin rose 139477.0% year-over-year to 503.66%, compared with a TTM value of 8372.08% through Sep 2025, down 564266.0%, and an annual FY2024 reading of 21128.88%, down 1772012.0% over the prior year.
  • Net Margin was 503.66% for Q3 2025 at Bicycle Therapeutics, up from 2703.84% in the prior quarter.
  • Across five years, Net Margin topped out at 300.39% in Q4 2023 and bottomed at 2703.84% in Q2 2025.
  • Average Net Margin over 5 years is 777.62%, with a median of 608.94% recorded in 2025.
  • The sharpest move saw Net Margin skyrocketed 189774bps in 2022, then tumbled -227854bps in 2025.
  • Year by year, Net Margin stood at 2254.62% in 2021, then soared by 84bps to 356.88% in 2022, then surged by 184bps to 300.39% in 2023, then decreased by -20bps to 239.65% in 2024, then plummeted by -310bps to 503.66% in 2025.
  • Business Quant data shows Net Margin for BCYC at 503.66% in Q3 2025, 2703.84% in Q2 2025, and 608.94% in Q1 2025.